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Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus R© in a 1-year prospec-
tive multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Der-
matophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were
evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolu-
tion of the combined symptom and medication score. Secondary end points included other effectiveness
outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improve-
ments in primary and secondary end points after 6 months compared with baseline. These differences
persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication
score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion: Acarovac Plus for 1 year was
effective and well tolerated in a real-life setting.
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Allergic rhinitis (AR) is a highly prevalent allergic disease and one of the most frequent reasons for medical
consultation [1]. Sensitization to house dust mite airborne allergens is recognized as a causative factor for both AR
and allergic asthma [2]. Among all dust mites, the prevalence of sensitization to Dermatophagoides pteronyssinus (D.
pter.) is the most common [3]. Avoidance of house dust mites is not always feasible, and patients worldwide are
suffering rhinitis symptoms such as runny nose, watery eyes, sneezing or nasal congestion that have a great impact
on their daily life.
Traditional pharmacotherapy with antihistamines or corticosteroids provides symptomatic relief but does not
offer long-term benefits, since the natural progression of the disease remains unaffected. Despite abundant treatment
options, many patients are not satisfied because those therapies are not always sufficient to control the symptoms,
especially in cases of moderate or severe allergic disease, or patients with concomitant allergic asthma [4,5]. In these
cases, treatment with specific immunotherapy is indicated.
Allergen-specific immunotherapy consists of administering the specific allergen to an allergic person in order
to increase their immunological tolerance and to decrease the symptoms associated with subsequent exposure to
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the causative allergen. This therapy addresses the immune cause of the disease, and today it is the only treatment
modality that, as recognized by the World Health Organization, in addition to effectively reducing allergic symptoms
and the need for symptomatic medication, also has the potential to alter the natural course of the disease [6].
Acarovac Plus R© is a purified allergen extract from D. pter. modified into an allergoid by treatment with
glutaraldehyde and adjuvanted with microcrystalline tyrosine (MCT). Previous studies demonstrated the clinical
and immunological efficacy and tolerability in a small-size, single-center, observational study [7,8].
The aim of the present study was to extend the analysis of the effectiveness of immunotherapy with a D. pter.
extract modified with glutaraldehyde and associated with MCT (Acarovac Plus) and to determine its tolerability in
adult patients with AR in a multicenter real-life setting.
Materials & methods
Study design
We performed a prospective, multicenter observational study, including adult patients with AR, with or without
asthma, caused by hypersensitivity to D. pter. who were eligible for treatment with specific immunotherapy according
to standard clinical practice.
This study was approved by the Ethics Committee of the Hospital Germans Trias i Pujol (Ref. EPA-14-023)
and met the ethical principles stated in the Declaration of Helsinki. Written informed consent was obtained from
all individual participants included in the study.
Participants
The study population consisted of adult patients aged between 18 and 65 years, with AR with or without asthma
secondary to hypersensitivity to D. pter. Diagnosis of AR was made on basis of patients’ clinical history and physical
examination.
Other inclusion criteria were as follows: clinical symptoms of AR caused by D. pter. for at least 1 year before
study initiation and for whom, in the investigator’s opinion, treatment with specific immunotherapy was indicated;
skin prick test result ≥3 mm in diameter for D. pter. in the previous 12 months; positive result for a specific IgE
to D. pter. of at least class 2 (greater than 0.7 kU/l measured by ImmunoCAP system; Thermo Fisher Scientific,
Waltham, MA, USA) at baseline; patients monosensitized to Dermatophagoides or polysensitized, provided that,
in the investigator’s opinion, the other sensitizations were not clinically relevant; the specialist prescribed Acarovac
Plus D. pter. Patients that presented sensitization to other clinically relevant perennial and seasonal allergens, except
for other mites, who had received previous immunotherapy for the allergen being tested or presented any of the
medical or social conditions listed in the Supplementary Information were excluded.
Immunotherapy
Acarovac Plus (Allergy Therapeutics, Worthing, UK), an extract of D. pter. modified into allergoid by treatment
with glutaraldehyde and associated with MCT as an adjuvant, was subcutaneously injected with increasing doses
in the initial phase, starting with 0.05 ml. Subsequent doses, administered with an interval of 1–2 weeks between
injections increase until reaching 0.5 ml in these steps: 0.05, 0.1, 0.3 ml. The treatment continued with injections
of 0.5 ml every 6 weeks until the end of treatment (dose escalation scheme is shown in Supplementary Table 1).
The total duration of the study was 13 months.
Definition of study outcomes
The primary end point was the mean change in the combined symptom and medication score (CSMS, 0–6 point
scale, Supplementary Table 2), as described by the European Academy of Allergy and Clinical Immunology [9],
collected for 4 weeks at baseline and after 6 months and 1 year of treatment. The following effectiveness variables
were also collected at baseline and 6 and 12 months: mean change in symptom score (daily symptom score) and
mean change in medication consumption score (daily medication score); percentage of ‘well and bad days’ [9];
evolution of rhinitis control following the criteria of the American Academy of Allergy Asthma & Immunology
and the American College of Allergy, Asthma & Immunology [10]; percentage of seriousness in the classification of
rhinitis (ARIA guideline) [2]. Changes in the sensitivity to D. pter., as determined by using specific nasal provocation
test (NPT), were assessed at baseline and at the end of the study [11].
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Table 1. Patients characteristics at baseline.








Previous immunotherapy 2 1.7
Allergic medication for rhinitis 103 87.3
Oral antihistamines 92 89.3
Topical antihistamines 7 6.8
Nasal corticosteroids 71 68.9
Oral corticosteroids 2 1.9
Additionally, the mean change in intensity of symptoms using a visual analog scale (VAS) was evaluated by the
patients, who also filled the ESPRINT-15 questionnaire [12] and TSQM-14 questionnaire [13] to measure changes
in their quality of life and treatment satisfaction, respectively.
The number, intensity and seriousness of adverse reactions to the treatment were recorded throughout the study.
Nasal provocation test
The NPT was carried out as described previously [8] following SEAIC guidelines [11]. An extended description can
be found in Supplementary Information and Supplementary Table 3.
Concomitant antiallergic medication
During treatment, patients could experience symptoms of rhinitis and/or asthma that needed additional treatment.
Antihistamines, nasal corticosteroids and oral corticosteroids were used in a stepwise manner if necessary, according
to usual clinical practice. In order to avoid interference with the skin tests and the NPT, washing out periods of the
rescue medications were established: 3 days after antihistamines and nasal corticosteroids for a NPT, and 5 days
after antihistamines for skin prick test.
Statistical analysis
Categorical variables have been described using absolute and relative frequencies (%). Continuous variables have
been described using the mean and standard deviation.
To compare patient subgroups with quantitative variables, nonparametric (Mann–Whitney and Kruskal–Wallis)
tests have been used. To compare the data between visits, non parametric (Wilcoxon or Friedman) tests have been
performed. Qualitative variables were calculated using the χ2 test or McNemar’s test. The statistical analysis was
performed using the SAS statistical package, version 9.4.
The calculation of the sample size has been established in accordance with ICH guidelines, which specify that
the number of patients should be enough to provide a valid response regarding the issues raised. Considering
that the primary end point of the study was the mean change in the CSMS at 12 months of follow-up, and the
standard deviation from the mean change in CSMS was estimated to be 7.3 from a previous study (Stelmach I et
al. [14]), a sample size of 142 patients would provide a precision of ±1.2 points for estimating the mean change in
the combined symptom and drug-consumption score, with a 95% CI. Assuming that 10% of cases could not be
analyzed due to losses, the number of patients to be enrolled amounts to 150. The calculations were made by the
PASS Sample Size software (PASS 11; NCSS, LLC).
Results
Study population
As shown in Figure 1, 141 patients were initially recruited, of which 118 met the selection criteria and were included
in the study for evaluation. Demographic, clinical and other patient characteristics are summarized in Table 1.
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108 continued at 6 months
20 lost follow-up
88 continued at 12 months
118 evaluable subjects
Figure 1. Study flow.
Table 2. Change in combined symptom and medication score.
Visit n Mean SD p-value†
CSMS (0–6) Baseline 103 1.60 1.01
After 6-months IT 88 1.10 0.98
After 1-year IT 78 0.79 0.91
Change CSMS After 6-months IT – Baseline 86 -0.44 0.91 0.0001
After 1-year IT – Baseline 76 -0.69 1.14 0.0001
After 1-year IT – After 6 months IT 77 -0.29 1.00 0.0026
†Wilcoxon test.
CSMS: Combined symptom and medication score; IT: Immunotherapy.
67 patients (56.8%) were female. The mean age was 33.6 years (SD = 9.55). Regarding preceding treatments with
immunotherapy, only two (1.7%) of the patients had previously received other vaccines, one (0.85%) of which
was for mite allergy. Oral antihistamines and nasal corticosteroids were the most frequently allergy medications
prescribed to patients during the study (89.3 and 68.9% of the patients at baseline, respectively).
Change of the combined symptom & medication score with the treatment
A mean decrease of 0.44 points (SD = 0.91) was obtained in CSMS between baseline and 6 months after medication
treatment (p < 0.0001), and 0.69 (SD = 1.14) between baseline and 1 year after medication treatment (p < 0.0001)
(Table 2). Statistically significant mean decrease differences were also detected from 6 months to 1 year of medication
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Table 3. Analysis of treatment effectiveness.
Visit n Mean SD p-value†
Change in number of well days
Total % of well days‡ Baseline 107 46.36 36.77
After 6-months IT 96 59.67 39.02
After 1-year IT 84 65.48 34.21
Change in the % of well days After 6-months IT – Baseline 96 10.86 39.82 0.0031
After 1-year IT – Baseline 84 15.05 43.59 0.0012
After 1-year IT – After 6 months IT 84 2.17 39.74 0.7658
Change in number of bad days
Total % of bad days‡ Baseline 105 15.03 23.62
After 6-months IT 90 7.22 16.98
After 1-year IT 80 7.14 19.54
Change in the % of bad days After 6-months IT – Baseline 89 -5.50 17.56 0.0005
After 1-year IT – Baseline 79 -3.75 22.82 0.0172
After 1-year IT – After 6 months IT 79 0.23 15.18 0.5700
Nasal provocation test
% NIPF drop and change Baseline (positive) 104 37.38 22.42
After 1-year IT (at the same concentration
as baseline visit)
54 24.53 22.90
NIPF change 54 -12.42 34.26 0.0076
Difference score and change Baseline (positive) 106 6.02 1.94
After 1-year IT (at the same concentration
as baseline visit)
55 4.16 2.50
Change 55 -2.16 2.66 0.0001
Well days: days without intake of rescue medication and a symptom score below 2 [9]. Bad days: a symptom score of 3 in any of the four rhinitis symptoms.
†Wilcoxon test.
‡The calculation of the percentage has been made over a total of 28 days before each visit.
IT: Immunotherapy; NIPF: Nasal inspiration peak flow.
treatment (p = 0.0026). Both daily-symptom score and mean daily-medication score showed a statistically significant
decrease after 6 months and 1 year of treatment compared with baseline too (Supplementary Table 4).
Additional efficacy outcomes
Secondary end points regarding efficacy of the immunotherapy are shown in Table 3. Percentage of well days was
significantly increased after 6 months (59.67 ± 39.02) and after 1 year (65.48 ± 34.21) of treatment versus baseline
visit (46.36 ± 36.77). At the same time, the percentage of bad days decreased at follow-up visits (7.22 ± 16.98 at
6 months, and 7.14 ± 19.54 at 1 year) compared with baseline visit (15.03 ± 23.62).
According to American Academy of Allergy Asthma & Immunology/American College of Allergy, Asthma &
Immunology criteria, the degree of rhinitis control was improved after each visit as shown in Figure 2. At baseline,
7.6% of patients had controlled rhinitis. The percentage increased to 45.7% of patients after 6 months of treatment
(p < 0.0001 in respect to baseline visit), and to 63.1% of patients at 1-year visit (p < 0.0001 in respect to baseline
visit and p = 0.0159 in respect to visit at 6 months). At the end of specific immunotherapy, only 2.4% of patients
could not control their rhinitis. Similar results were obtained following ARIA guidelines (Supplementary Table 5).
The number of patients with persistent AR decreased from 79.7% at the baseline visit to 15.5% at 1-year visit (p <
0.0001). Symptom intensity was also reduced after the immunotherapy. Moderate-severe AR intensity was found
in 83.1% of the evaluable patients at baseline visit versus 20.2% at 1-year visit (p < 0.0001).
We found a decrease in patient sensitivity to D. pter. after immunotherapy in the NPT (Table 3). The mean %
nasal inspiration peak flow drop before the treatment was 37.38% (SD = 22.42) and 24.53% (SD = 22.90) after 1
year of treatment (at the same concentration that was positive at the baseline visit) with an observed absolute mean
change of -12.42% (SD = 34.26; p = 0.0076). Statistically significant differences were detected in the evolution
of symptom score on nasal challenge test (p < 0.0001) where a mean change of -2.16 (SD = 2.66) was observed
between baseline visit and the visit at 1 year of treatment.
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Figure 2. Degree of rhinitis control according to American Academy of Allergy Asthma & Immunology/American
College of Allergy, Asthma & Immunology guidelines.
*p < 0.0001 (McNemar test) versus basal. Controlled rhinitis: does not interfere with everyday activities;
<2 days/week: sneezing, itching, congestion, ocular symptoms. Partially controlled rhinitis: some interference with
everyday activities; 2–6 days/week: sneezing, itching, congestion, ocular symptoms. Not controlled rhinitis: high
degree of interference with everyday activities; daily sneezing, itching, congestion, ocular symptoms.
Table 4. Analysis of immunotherapy effects on patients’ quality of life and treatment satisfaction.
Visit n Mean SD p-value†
ESPRINT-15: Quality of life questionnaire
Overall score ESPRINT-15 Baseline 111 2.62 1.56
After 6-months IT 95 1.33 1.05
After 1-year IT 82 1.16 1.25
Change overall score ESPRINT-15 After 6-months IT – Baseline 94 -1.30 1.56 0.0001
After 1-year IT – Baseline 80 -1.29 1.59 0.0001
TSQM: Questionnaire on treatment satisfaction 0–100 scale
Global satisfaction After 6 months IT 98 71.65 16.80
After 1-year IT 83 73.41 18.58
†Wilcoxon test.
IT: Immunotherapy.
VAS (scale 0–10 cm) was used by the patients to evaluate symptom intensity. A mean change decrease in the
VAS in respect to baseline visit of -2.98 (SD = 2.96) cm at the 6 months visit (p < 0.0001), and -3.55 (SD = 2.89)
cm at 1-year visit (p < 0.0001) was observed (Supplementary Table 6).
Changes in patients’ quality of life and treatment satisfaction were measured by the ESPRINT-15 and TSQM
questionnaires as shown in Table 4. Statistically significant differences were detected in all the score dimensions
of ESPRINT-15 (symptoms, daily activities, sleep and psychological impact) and total score ESPRINT-15 during
the study in respect to the baseline value. A mean decrease of 1.30 (SD = 1.56) points was obtained in overall
score ESPRINT-15 (scale 0–6) between baseline and 6 months after immunotherapy (p < 0.0001), and 1.29 (SD
= 21.59) between baseline and 1 year after immunotherapy (p < 0.0001). The mean global satisfaction with the
treatment (TSQM, score 0–100) was high after 6 months of treatment (71.65 ± 16.80) and after 12 months of
treatment (73.41 ± 18.58).
58 Immunotherapy (2020) 12(1) future science group
Immunotherapy for allergic rhinitis: RWD Research Article
Safety outcomes
18 patients (15.3%) showed 87 adverse reactions. They were mostly local (95.4%), and only four mild systemic
reactions were reported. Those included a 24-year-old male patient that suffered a systemic reaction consisting of
discomfort and headache on two separate occasions, 24 h after the maintenance dose was administered (0.5 ml).
These reactions disappeared spontaneously at 48 h. The causal relationship was classified as ‘possible’ by the
investigator. No deaths or serious adverse events were recorded. Supplementary Table 7 provides a summary of the
safety end points assessed throughout the study.
Discussion
The present study demonstrated that Acarovac Plus, a marketed mite-allergoid immunotherapy adjuvanted with
MCT, is an effective and safe treatment for adult patients with AR. The primary end point was met, with reduction
of allergic symptoms and reduction of the medication needed to alleviate symptoms of allergy after 6 months
and 12 months of treatment. Importantly, other effectiveness variables such as symptom intensity, level of rhinitis
control, percentage of well/bad days and nasal provocation test were also significantly improved, and no serious
adverse events were reported. Moreover, patients reported a positive impact of the treatment in their quality of life
and a high degree of satisfaction with the treatment.
Allergens for specific immunotherapy are often coadministered along with adjuvants to increase the allergen
immunogenicity and to modulate the immune response. Aluminum hydroxide is the most commonly used
adjuvant for vaccines. However, there are still concerns associated with aluminum use and its accumulation in long-
term therapy [15]. Instead, Acarovac Plus is combined with MCT, a biodegradable adjuvant with high adsorption
capacity [16] and a half-life of 48 h [17], making MCT an optimal adjuvant to modulate and enhance the immune
response.
Immunotherapy is an alternative to conventional pharmacotherapy in the treatment of AR. Instead of a palliative
effect, allergen immunotherapy aims to alter the normal progression of allergic diseases and could represent a cure for
AR. In fact, many randomized clinical trials and meta-analyses have robustly demonstrated that immunotherapy is
clinically effective in reducing the symptoms and medication consumption in respiratory allergy [18–24]. Nevertheless,
real-life studies offer the opportunity of obtaining outcomes suitable in clinical practice, as controlled trials do not
mirror the real patients’ population observed in clinical practice [25]. In this real-life noninterventional study, we
have found that treatment with Acarovac Plus reduces both the allergic symptoms and the medication needed to
ease the AR, with a CSMS mean decrease of 0.69 points (a 43% reduction compared with baseline) after 1 year of
immunotherapy. The observed treatment effect exceeds the results of many immunotherapy randomized controlled
trials (with CSMS reductions of up to 26% [18]) and the recommendations of the World Allergy Organization
regarding the ‘minimal clinically relevant efficacy’ of 20% in immunotherapy clinical trials [26]. Moreover, this
decrease in CSMS was accompanied by a significant improvement in other allergy outcomes, such as percentage of
well days (65.48% after 1 year of Acarovac Plus treatment vs 46.36% at baseline) and degree of rhinitis control,
with 63.1% of patients reporting controlled AR after 1-year immunotherapy treatment compared with 7.6% at
baseline.
The burden of AR goes beyond clinical symptoms affecting patients’ quality of life. People with AR experience
negative impacts on sleep, social life and their daily activities, affecting patients’ performance at work [27–29]. A
cross-sectional study found that AR patients experience a higher negative impact on daily activities than patients
with hypertension or diabetes mellitus [30]. Accordingly, the GA2LEN group together with the European Academy
of Allergy and Clinical Immunology have estimated that AR is generating more than 100 billion euros of losses
per annum due to decreased work productivity associated with the pathology [31]. However, there is very limited
data regarding quality of life of AR patients in a real-life setting. Our study showed that Acarovac Plus treatment
enhanced patients’ health-related quality of life in all the dimensions measured by the ESPRINT-15 questionnaire
(symptoms, daily activities, sleep and psychological impact). The overall ESPRINT-15 score (scale 0–6) was
decreased by 1.29 points after 1 year of immunotherapy treatment, thus confirming the positive impact of Acarovac
Plus as an enhancer of quality of life in patients receiving standard care.
No serious adverse events were recorded in our study. Only 15.3% of patients had adverse reactions, most of
them (95.4%) being local, demonstrating that Acarovac Plus is well tolerated. These data are in agreement with
previous reviews and recent observational studies reporting that local reactions are common after immunotherapy
treatment [32–34].
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This study has several strengths, including its multicenter nature and the evaluation of multiple variables to
assess treatment effect. Many prospective observational immunotherapy studies are based on patient’s characteristics,
medication data and subjective symptoms scores. Our study, however, also includes objective parameters to measure
treatment effectiveness, like the NPT, a reliable method that reproduces the allergic reaction. Moreover, it is a real-life
study, allowing us to determine the effect of Acarovac Plus in the general population, following standard procedures
and standard of care and contributing to the growing importance of real-life studies in allergen immunotherapy [25].
However, it also has some limitations inherent to an observational study. Since it is observational, unblinded
outcome assessment cannot be avoided. In addition, safety and efficacy of this treatment should also be explored
in other populations (e.g., children and adolescents) and with other mite allergens (D. farinae, mixture of D.
pteronyssinus and D. farinae, Lepidoglyphus destructor or Blomia tropicalis).
The number of patients planned to be recruited for the study was 150. Finally, just 118 patients were evaluable
for the analysis at baseline. Although this fewer-than-expected number of evaluable patients could have caused a
low statistic power to detect differences before and after treatment, it did not happen. After 12 months of follow-up,
30 of the 118 evaluable patients were lost. Some of them could not be evaluated at 12 months because they had
improved their symptoms and decided not to continue with the vaccine (data not shown). To determine whether
the differences in the main variable (CSMS) measured at baseline and at 12 months could be overestimated by
the number of lost patients, who could abandon the study by treatment ineffectiveness, we performed a sensitivity
analysis, considering the worst scenario (no improvement): Lost patients were asigned the last available CSMS value
(e.g., baseline score was assigned to patients with data not available at 6 months, and 6-month score was assigned
to patients with data not available at 12 months). Once the analysis was repeated, statistically significant differences
in CSMS between baseline and at 12 months of treatment (mean decrease of 0.67 points, SD 1.03; p < 0.0001)
were shown.
The absence of a control group makes it difficult to ascertain the significance of these results. However, it is not
probable that the effects observed for Acarovac Plus are exclusively due to a placebo effect, since the study includes
a measure of the changes in the sensitivity to D. pter. by using a specific NPT, which is an objective outcome that
is not depending on patient or investigators opinions. On the other hand, study results should be confirmed using
a more robust design study, ideally a double-blind, placebo-controlled clinical trial.
Conclusion
In this real-life study, we demonstrate that treatment with Acarovac Plus in adult patients with AR sensitized to
D. pter. is effective with a balanced safety and tolerance profile. Controlled trials should be performed in order to
confirm these results and quantify a possible placebo effect.
Summary points
• Previous studies demonstrated the clinical and immunological efficacy and tolerability of Acarovac Plus R© in a
small-size, single-center, observational study.
• In a 1-year prospective multicentered real-life study, Acarovac Plus produced a significant decrease of allergic
symptoms and reduction of the medication needed to alleviate symptoms of allergy after 6 months and
12 months of treatment.
• Symptom intensity, level of rhinitis control, percentage of well/bad days and nasal provocation test were
significantly improved with Acarovac Plus immunotherapy.
• Patients reported a positive impact of the treatment in their quality of life (ESPRINT-15 questionnaire) and a high
degree of satisfaction with the treatment (TSQM questionnaire).
• Acarovac Plus was well tolerated and no serious adverse events were reported during the 1-year follow-up period.
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